A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice
Authors:
- Su Young ChaeSCSu Young Chae
- Sohee SonSSSohee Son
- Tae Hyung KimTKTae Hyung Kim
- Key An UmKUKey An Um
- Yu Seok YounYYYu Seok Youn
- Seulki LeeSLSeulki Lee
- Kang Choon LeeKLKang Choon Lee
- 1 February 2009
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 133 (3) , 172-177
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: Design, preparation, and biological evaluationEuropean Journal of Pharmaceutics and Biopharmaceutics, 2008
- Preparation, Characterization, and Application of Biotinylated and Biotin−PEGylated Glucagon-Like Peptide-1 Analogues for Enhanced Oral DeliveryBioconjugate Chemistry, 2007
- Biological activity of AC3174, a peptide analog of exendin-4Regulatory Peptides, 2007
- Incretins and other peptides in the treatment of diabetesDiabetic Medicine, 2007
- Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stabilityBiochemical Pharmacology, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- New Therapeutic Strategies for the Treatment of Type 2 Diabetes Mellitus Based on IncretinsThe Review of Diabetic Studies, 2005
- Oral Delivery of Peptide DrugsBioDrugs, 2005
- Oral Delivery of Mono-PEGylated sCT (Lys18) in Rats: Regional Difference in Stability and Hypocalcemic EffectPharmaceutical Development and Technology, 2005
- Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitroMetabolism, 2001